A US- based oncologist shares perspectives on HR+/HER2- breast cancer epidemiology, in-depth insights into the treatment landscape for various settings and lines of therapy, patient progression, and the promising emerging therapies/regimens. The interview highlights HR+/HER2- breast cancer as a disease in which endocrine therapy is the backbone, with escalation guided by stage, menopausal status, nodal involvement and genomic risk testing.

This interview was conducted on August 06, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.